LOGIN  |  REGISTER
Cue Biopharma
C4 Therapeutics

SomaLogic to Participate in the 41st Annual J.P. Morgan Healthcare Conference

BOULDER, Colo., Dec. 29, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference.

SomaLogic will present at the conference on Thursday, January 12, 2023 at 11:15 a.m. Pacific Time. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at https://investors.somalogic.com.

About SomaLogic

SomaLogic (Nasdaq: SLGC) seeks to deliver precise, meaningful and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from SomaLogic’s personalized measurement of important changes in an individual’s proteins over time. For more information, visit www.somalogic.com and follow @somalogic on Twitter.

Media Contact
Emilia Costales
720-798-5054
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Investor Contacts
Marissa Bych
Gilmartin Group LLC
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Viking Therapeutics

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page